|
EP1276468A1
|
|
Use of particulate vectors in immunomodulation
|
|
EP1276508A2
|
|
A particulate complex for administering nucleic acid into a cell
|
|
AU3186501A
|
|
Amphilic and ionic polymer matrixes and derivatives thereof
|
|
FR2805270A1
|
|
BIOELIMINABLE CATIONIC POLYMERS AND MATRICES WITH CONTROLLED DEGRADATION
|
|
US5968794A
|
|
Biodegradable particulate vector for transporting molecules having biological activity
|
|
AU5668898A
|
|
Homogeneously charged particulate vector and pharmaceutical or cosmetic composition containing same
|
|
AU5563898A
|
|
Conjugates of a particle vector and oligonucleotides, process for their preparation, and pharmaceutical compositions containing them
|
|
CN1241940A
|
|
Mucosal administration of substances to mammals
|
|
US6096291A
|
|
Mucosal administration of substances to mammals
|
|
EP0814835A1
|
|
Method for enhancing immunogenicity, product obtained and pharmaceutical composition
|
|
US6013284A
|
|
Synthetic particulate vectors and preparation process
|
|
EP0547191A1
|
|
Particulate vector having selective tropism, method of preparation and pharmaceutical composition
|
|
KR100258521B1
|
|
Biodegradable particulate vector and method of synthesis
|
|
EP0542965A1
|
|
Particle for use as a milk fat globule substitute, composition containing same and process for the preparation of said particle
|
